Grant: CCI Applied Research and Development Grants

This project is built on an on-going successful research collaboration between Noa Therapeutics and TransBIOTech where promising preliminary data on the capabilities of Noa Therapeutics proprietary compounds to improve key phenotypes observed in animal models of skin disorders such as atopic dermatitis (AD). Noa Therapeutics is a preclinical biotechnology company pioneering the development of trimodal therapeutics (TMTs) with a tailored ligand structure; addressing the three primary drivers of inflammatory diseases involving barrier function by 1) restoring barrier function, 2) resolving inflammation, 3) protecting against infection. Noa’s suite of TMTs is composed of non-steroidal small molecules adopt synergistic therapeutic attributes to drive three discrete modes of action, to treat the underlying disease state. AD is a prevalent chronic skin condition affecting both adults and children, with complex underlying mechanisms involving genetic susceptibility, environmental triggers, and immune system dysregulation. Previous results suggest that TMTs developed by Noa Therapeutics could lead to a new treatment option in AD, by restoring barrier function and decreasing inflammation. However, to translate the development of the NOA suite into positive clinical outcomes, further work is required to thoroughly understand the mechanisms of action. The proposed project aims to characterize the immune and skin barrier dysregulation in a murine model of AD induced by MC903 and to identify key biomarkers modulated by the administration of NOA-104 in order to identify the underlying mechanism of action and optimize its impact on AD pathways to enhance Noa's product suite. This novel multimodal approach is uniquely aligned to address unmet needs within immune disease; creating an opportunity to redefine immune disease treatment for unprecedented clinical impact.